TABLE 1

Characteristics of A. baumannii strains used in this study

StrainCountry of originYear(s)SourceICL (ST)aResistancebGaN IC90 (μM)cBiofilm (OD600)dReference
ATCC 19606TUSA1948UrineNon-ICL (931)SusceptibleND0.108 ± 0.007 36
ATCC 17978France1951BloodNon-ICL (959)Susceptible3.8 ± 0.00.044 ± 0.011 37
AYEFrance2001Urine1 (231)MDR10.7 ± 1.30.069 ± 0.011 38
A458Estonia2001–2004Clinical (ARPAC project)1 (NA)MDR21.2 ± 1.70.104 ± 0.012 39
A472Poland2001–2004Clinical (ARPAC project)1 (245)MDR7.5 ± 0.40.120 ± 0.016 39
C13-373Italy2007Blood1 (95)MDR31.0 ± 3.20.142 ± 0.018 40
C6-397Italy2007Blood1 (196)MDR28.9 ± 0.20.133 ± 0.019 40
ACICUItaly2005Cerebrospinal fluid2 (437)MDR14.0 ± 2.10.134 ± 0.012 16
A60Argentina2001–2004Clinical (ARPAC project)2 (241)MDR7.7 ± 0.10.148 ± 0.022 40
A491India2001–2004Clinical (ARPAC project)2 (NA)MDR14.0 ± 2.30.085 ± 0.020 40
LUH5875The Netherlands1997Blood3 (NA)eMDR14.5 ± 5.20.104 ± 0.020 41
A377Germany2001–2004Clinical (ARPAC project)3 (187)MDR4.0 ± 0.00.120 ± 0.015 40
  • a ICL, international clonal lineage; ST, sequence type according to the multilocus sequence typing (MLST) Oxford scheme (http://pubmlst.org/abaumannii/ ); NA, not assigned.

  • b MDR, multidrug resistant.

  • c The IC90 in HS was determined as described by Antunes et al. (7);.ND, not determined due to poor growth.

  • d Biofilm formation was determined after 48-h growth in MH broth.

  • e ST3 according to the MLST Pasteur scheme (http://pubmlst.org/abaumannii/ ).